Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Effect of the VR Technology on Recovery of the Autonomic Nervous System in Volunteers Affected by Stress

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03532152
Recruitment Status : Completed
First Posted : May 22, 2018
Last Update Posted : April 16, 2019
Sponsor:
Collaborator:
Pharmaxi LLC
Information provided by (Responsible Party):
Pure Purr LLC

Brief Summary:

The study assess the effect of the VR technology (Pure Purr technology) on the recovery of the autonomic nervous system in healthy volunteers affected by moderate stress. Study subject randomized into two groups: in Group 1 volunteers first be tested with the VR headset A, and during the next visit- headset B. Group 2 volunteers first be tested with the VR headset B, and during the next visit- headset A. Before, after and during VR session was conducted stress modulation and ECG recording.

The Pure Purr technology combines several audio and visual stimuli aimed at activation of the parasympathetic nervous system. Therefore, this study will investigate the effect of this technology on the recovery of autonomic nervous system performance after moderate stress.


Condition or disease Intervention/treatment Phase
Stress Device: Pure Purr VR technology Device: Sham VR technology Not Applicable

Detailed Description:
Pure Purr technology is based on discoveries in neurophysiology, medicine, acoustics, and computer engineering, which are used to initiate the physiological process of recreation, i.e. allostasis. Literally this term means "achieving stability through change". This is an active mechanism playing a part in normalization of the tone of the autonomic nervous system and maintaining stability of the body internal environment. The condition in which all our functions are implemented fully and sparingly in response to the load, and the level of adaptation remains high for a long time. Pure Purr is a software and hardware complex for relaxation and recreation based on a virtual reality headset with a display with sufficient resolution, built-in processor, memory, and extended-range stereo speakers. Positive effect on the cognitive function of the brain and the system of neurohumoral regulation is achieved due to the synchronous actuation of a number of stimuli, such as: visual sequence enhanced by the effect of virtual reality, harmonious music with the binaural rhythm technology, and modified cat purrs. Currently, the use of each technology is a scientifically proven trigger for the activation of individual parts of the human nervous system. And combining them in one software complex enhances the overall effect.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 94 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Investigator)
Primary Purpose: Other
Official Title: Randomized, Prospective, Sham-controlled, Blinded, Cross-over Clinical Study of the Effect of the Virtual Reality (VR) Technology on Recovery of Indicators of the Autonomic Nervous System in Healthy Volunteers Affected by Moderate Stress
Actual Study Start Date : February 26, 2018
Actual Primary Completion Date : November 14, 2018
Actual Study Completion Date : November 14, 2018

Arm Intervention/treatment
Active Comparator: Pure Purr VR technology

The arm will use the virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen.

The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes.

Device: Pure Purr VR technology

The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.

The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate.


Sham Comparator: Sham VR technology

The arm will use the headset with audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.

The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes.

Device: Sham VR technology
The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.




Primary Outcome Measures :
  1. Power in high frequency range (HF) [ms2] [ Time Frame: The outcome measure will be assessed between two visits with minimum interval 24 up to seven days ]
    Change from Power in high frequency range (HF) [ms2] at 5 minutes before and after VR technology using


Secondary Outcome Measures :
  1. The square root of the mean of the sum of the squares of differences between adjacent NN intervals (rMSSD), [ms] [ Time Frame: The outcome measure will be assessed between two visits with minimum interval 24 up to seven days ]
    Change from rMSSD variable at 5 minutes before and after VR technology using

  2. Standard deviation of all NN intervals (SDNN), [ms] [ Time Frame: The outcome measure will be assessed between two visits with minimum interval 24 up to seven days ]
    Change from SDNN variable at 5 minutes before and after VR technology using

  3. Ratio Power in low frequency range [ms2]/ Power in high frequency range [ms2] (Ratio LF [ms2]/HF [ms2]) [ Time Frame: The outcome measure will be assessed between two visits with minimum interval 24 up to seven days ]
    Change from Ratio LF [ms2]/HF [ms2] at 5 minutes before and after VR technology using

  4. Total power (TP), [ms2] [ Time Frame: The outcome measure will be assessed between two visits with minimum interval 24 up to seven days ]
    Change from Total power (TP) variable at 5 minutes before and after VR technology using

  5. Heart Rate (HR) variable. [ Time Frame: The outcome measure will be assessed between two visits with minimum interval 24 up to seven days ]
    Change from Heart Rate (HR) variable at 5 minutes before and after VR technology using

  6. BP (both systolic and diastolic blood pressure) variable. [ Time Frame: The outcome measure will be assessed between two visits with minimum interval 24 up to seven days ]
    Change from systolic and diastolic blood pressure at 5 minutes before and after VR technology using

  7. Spielberger state-trait anxiety inventory (STAI) variable. [ Time Frame: The outcome measure will be assessed between two visits with minimum interval 24 up to seven days ]

    Change from STAI variable at 5 minutes before and after VR technology using. STAI-Examination of the level of situational anxiety.

    Statement for еxamination:

    1. Calm down
    2. Safe
    3. Tense
    4. Annoyed
    5. Comfortable
    6. Upset
    7. Concerned with future misfortunes
    8. Relaxed
    9. Anguished
    10. At ease
    11. Self-confidence
    12. Nervous
    13. Restless
    14. Downhearted
    15. Rested
    16. Satisfied
    17. Concerned
    18. Stunned
    19. Happy
    20. I fell good

    The range for each subscale from 1 to 4 point.

    Processing of results:

    Calculate the total score based on answers given by volunteers.

    While interpreting the results, use the following levels of anxiety:

    • up to 30 points — low,
    • 31 - 44 points — moderate;
    • 45 and more — high.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Females and males 20-60 years old;
  2. Volunteers have no history of cardiovascular diseases;
  3. Volunteers have no essential abnormalities on the ECG;
  4. Normal or moderate level of situational anxiety based on the Spielberger State-Trait Anxiety Inventory (STAI);
  5. Signed Informed Consent Form for participation in the study.

Exclusion Criteria:

  1. Intolerance to the VR technology;
  2. HR 110 bpm or below 50 bpm;
  3. RR above 23 breaths per minute;
  4. Abuse of alcohol, psychotropic substances and narcotic agents;
  5. Smoking more than 100 cigarettes a week;
  6. Administration of medicinal products for the treatment of cardiovascular and nervous system diseases 3 days prior to participation in the study;
  7. Drinking tonics and energy drinks for at least 2 hours prior to participation in the study;
  8. Severe or acute forms of respiratory, urogenital, gastrointestinal, haematological, metabolic, endocrine, or neurological diseases;
  9. Mental disorders, which, in the opinion of the investigator, may distort the results of the study;
  10. Participation in any clinical study over the last 3 months prior to enrolment to the study;
  11. Parkinson's disease, Parkinson's symptoms, tremor, restless leg syndrome, and other motility disorders;
  12. Pregnancy;
  13. Any disease of the thyroid gland.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03532152


Locations
Layout table for location information
Ukraine
Doctor Sam Medical Network
Kyiv, Kyiv Region, Ukraine
Sponsors and Collaborators
Pure Purr LLC
Pharmaxi LLC
Investigators
Layout table for investigator information
Principal Investigator: Sam Aganov, Ph.D. Dr. Sam LLC
  Study Documents (Full-Text)

Documents provided by Pure Purr LLC:
Study Protocol  [PDF] January 29, 2018


Layout table for additonal information
Responsible Party: Pure Purr LLC
ClinicalTrials.gov Identifier: NCT03532152    
Other Study ID Numbers: PurePurr-001
First Posted: May 22, 2018    Key Record Dates
Last Update Posted: April 16, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pure Purr LLC:
VR
moderate stress